Menu

Neuropharmacologist Arvid Carlsson Dies at 95

The Nobel laureate’s discoveries led to a treatment for Parkinson’s disease.

Jul 2, 2018
Sukanya Charuchandra
Arvid Carlsson
WIKIMEDIA, VOGLER

Arvid Carlsson, a Swedish pharmacologist whose discovery of dopamine’s role in Parkinson’s disease revolutionized research into the condition, died on June 29. He was 95.

“Arvid Carlsson is the originator of several major discoveries that led to dramatic improvements in quality of life for millions of patients with neurological and psychiatric disorders,” Agneta Holmäng, dean of the Sahlgrenska Academy, says in a statement from the University of Gothenburg, where Carlsson was an emeritus professor of pharmacology.

Born into an academic family in Uppsala, Sweden, in 1923, he began studying medicine at the University of Lund in 1941. Carlsson completed his medical and doctoral degrees in 1951. During that period, he served in the Swedish military forces on-and-off for two years. In 1959, he became a professor of pharmacology at the University of Lund.

Prior to Carlsson’s research into dopamine, the scientific community believed the molecule was merely responsible for the formation of norepinephrine. His work, in 1957, with rabbits that exhibited movement difficulties revealed dopamine’s role in and led to the development of therapies for the neurodegenerative disorder Parkinson’s disease. Carlsson used L-dopa, a precursor of dopamine, to treat the rabbits. This compound is now used to ameliorate Parkinson’s symptoms in patients.

In 2000, Carlsson won the Nobel Prize in Physiology or Medicine for this work. “The award that you get from patients, compared to all the awards I have received, is much more important,” Carlsson said in a podcast recorded for the Sahlgrenska Academy in 2016.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.